10 November 2004 – LAWFUEL – Law, legal, securities law news – DLA LLP and Gray Cary have together advised Invitrogen Corporation the NASDAQ listed biotech company on the US$65,000,000 acquisition by its UK subsidiary company, Invitrogen Europe Limited, of DNA Research Innovations Limited (“DRI”), a gene testing service provider.

This is the latest of a series of acquisitions and fundraisings by Invitrogen involving Gray Cary but is the first time that DLA has acted for Invitrogen.
The DLA team was led by corporate partner Tom Whelan assisted by Nick Fegan and Lucy Skidmore (Corporate) and Sian Croxon and Selina Taylor (TMC). The Gray Cary team was lead by corporate partner Jeff Baglio assisted by Christian Waage and Matt Leivo (Corporate) and Mark Wicker (IP).

Tom Whelan said: “This was a particularly interesting project because it represents one of the first deals jointly staffed with lawyers from DLA and Gray Cary since their merger with Piper Rudnick was announced in October. The deal required first rate project management as it involved over fifty vendors and was completed within 5 weeks of lawyers being instructed. The successful completion of the transaction on time is a testament to the rapport that we have already built up with Jeff and his team at Gray Cary.”